epoprostenol (veletri) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Epoprostenol (marketed as FLOLAN, VELETRI) is a prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. Epoprostenol (PGI2, PGX, prostacyclin), a metabolite of arachidonic acid, is a naturally occurring prostaglandin with potent vasodilatory activity and inhibitory activity of platelet aggregation. FLOLAN (epoprostenol sodium) for Injection is a sterile sodium salt formulated for intravenous (IV) administration. Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume. The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. No major effects on cardiac conduction have been observed. Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. No available chemical assay is sufficiently sensitive and specific to assess the in vivo human pharmacokinetics of epoprostenol. FLOLAN is indicated for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension associated with the scleroderma spectrum of disease in NYHA Class III and Class IV patients who do not respond adequately to conventional therapy.   NCATS

  • SMILES: CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(=C/CCCC(=O)O)\C[C@H]12
  • InChIKey: KAQKFAOMNZTLHT-OZUDYXHBSA-N
  • Mol. Mass: 352.47
  • ALogP: 3.41
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$13.2600 - $46.8400

Australia

$25.8020 - $45.9985
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

(5z,13e)-(15s)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate | (5z,9alpha,11alpha,13e,15s)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid | epoprostenol | epoprostenolsodium | epoprostenol sodium | epoprostrenol | flolan | pgi2 | pg-i2 | pgx | prostacyclin | prostaglandin i2 | prostaglandin x | u-53217 | u-53217a | vasocyclin | veletri

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue